Panacea Acquisition II (Panacea Acquisition II) ROCE % : -0.51% (As of Dec. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Panacea Acquisition II ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Panacea Acquisition II's annualized ROCE % for the quarter that ended in Dec. 2022 was -0.51%.

Panacea Acquisition II ROCE % Historical Data

The historical data trend for Panacea Acquisition II's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panacea Acquisition II ROCE % Chart

Panacea Acquisition II Annual Data

Trend

Dec21

Dec22

ROCE %

-0.56

Panacea Acquisition II Quarterly Data
	Jan21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
ROCE %	Get a 7-Day Free Trial			-	-0.71	-0.53	-0.50	-0.51

Panacea Acquisition II ROCE % Calculation

Panacea Acquisition II's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-0.975	/	( ( (173.555 - 0.296)	+	(175.12 - 0.434) )	/ 2 )
	=	-0.975	/	( (173.259	+	174.686)	/ 2 )
	=	-0.975	/	173.9725
	=	-0.56 %

Panacea Acquisition II's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Sep. 2022 )		(Q: Dec. 2022 )
	=	-0.884	/	( ( (173.849 - 0.396)	+	(175.12 - 0.434) )	/ 2 )
	=	-0.884	/	( ( 173.453	+	174.686 )	/ 2 )
	=	-0.884	/	174.0695
	=	-0.51 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.

Panacea Acquisition II (NAS:PANA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Panacea Acquisition II ROCE % Related Terms

Thank you for viewing the detailed overview of Panacea Acquisition II's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Panacea Acquisition II (Panacea Acquisition II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Panacea Acquisition Corp II (NAS:PANA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

357 Tehama Street, Floor 3, San Francisco, CA, USA, 94103

Website

Panacea Acquisition Corp II is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Executives

Ecor1 Capital Fund Qualified, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital, Llc	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Oleg Nodelman	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Capital Fund, L.p.	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Ecor1 Venture Opportunity Fund, Lp	director, 10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Biotech Opportunity Gp, Llc	director, 10 percent owner	1370 TRANCAS STREET, SUITE 176, NAPA CA 94558
Ecor1 Panacea Holdings Ii, Llc	director, 10 percent owner	357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Douglas E Williams	director	C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Douglas E. Giordano	director	C/O PFIZER INC., 235 EAST 42ND STREET, NEW YORK NY 10017
Nina S Kjellson	director	C/O INTERWEST PARTNERS, 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Praveen P. Tipirneni	director	C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Sarah Marriott	director, officer: Secretary	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Perlen	officer: Chief Financial Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Caroline Stout	officer: Chief Investment Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103
Scott Platshon	officer: Chief Operating Officer	C/O ECOR1 CAPITAL, 357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO CA 94103